KLRS - Kalaris Therapeutics EV/EBITDA Multiple

Corporate company logo of Kalaris Therapeutics (KLRS)

Kalaris Therapeutics Inc (KLRS) is implementing advanced antibodies and gene therapies to combat ocular pathologies, aiming for a large-scale expansion of its product portfolio to achieve sector dominance. The confirmed price history on the EV/EBITDA chart at GURU.Markets is recorded at 0.00. The project's success relies on the flawless transportation of biomaterials under extreme cold, ensuring the integrity of the therapy during delivery to medical centers.

KLRS Kalaris Tx: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/17/2026

Analytical breakdowns for Kalaris Therapeutics Inc

- stock price and consensus target price:
Fundamental company analysis:Kalaris Tx KLRS
Original product of Kalaris Therapeutics

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation and amortization, allowing for an assessment of asset value relative to the ability to generate cash flow. For Kalaris Therapeutics Inc (KLRS), which is in the clinical trial stage without revenue, this calculation reveals a critical gap between the company's valuation and negative operating leverage, clearly reflecting the EV/EBITDA multiple level of a capital-intensive enterprise.

Competitors of Kalaris Therapeutics Inc

Gilead Sciences, Inc. - Enterprise Value to EBITDA Ratio|Cidara Therapeutics, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio CureVac NV CVAC|Valneva Pharma (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Corp (VIR) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio SIGA|Emergent BioSolutions (EBS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharma (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio Invivyd|EV/EBITDA Multiple ENTA (enanta.com)|INO: Enterprise Value to Operating Income Before Depreciation|hillevax.com - EV/EBITDA Multiple|Company Value to EBITDA dyadic.com|NanoViricides, Inc. (NNVC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TLPH (Talphera Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cocrystal|Enterprise Value to EBITDA Ratio trawspharma.com (TRAW)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dogwood Therapeutics, Inc. (DWTX)|Total Company Value to Operating Income Before Depreciation Ratio Qualigen Therapeutics|EV/EBITDA Multiple ALVR (allovir.com)|EV/EBITDA Multiple VBI Vaccines Inc VBIV|VIRI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VXRT (vaxart.com)